Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion

被引:15
作者
Dhaese, S. A. M. [1 ]
Colin, P. [2 ,3 ]
Willems, H. [1 ]
Heffernan, A. [4 ,5 ,6 ]
Gadeyne, B. [1 ]
Van Vooren, S. [7 ]
Depuydt, P. [1 ]
Hoste, E. [1 ]
Stove, V [7 ,8 ]
Verstraete, A. G. [7 ,8 ]
Lipman, J. [4 ,9 ,10 ]
Roberts, J. A. [4 ,6 ,9 ,11 ]
De Waele, J. J. [1 ]
机构
[1] Ghent Univ Hosp, Dept Crit Care Med, C Heymanslaan 10, B-9000 Ghent, Belgium
[2] Univ Groningen, Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands
[3] Univ Ghent, Lab Med Biochem & Clin Anal, Ghent, Belgium
[4] Univ Queensland, Univ Queensland Ctr Clin Res, Fac Med, Brisbane, Qld, Australia
[5] Griffith Univ, Sch Med, Southport, Qld, Australia
[6] Univ Queensland, Ctr Translat Antiinfect Pharmacodynam, Sch Pharm, Brisbane, Qld, Australia
[7] Univ Ghent, Dept Diagnost Sci, Ghent, Belgium
[8] Ghent Univ Hosp, Dept Lab Med, Ghent, Belgium
[9] Royal Brisbane & Womens Hosp, Dept Intens Care Med, Brisbane, Qld, Australia
[10] CHU Nimes, Dept Anesthesiol & Crit Care, Nimes, France
[11] Royal Brisbane & Womens Hosp, Dept Pharm, Brisbane, Qld, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
Piperacillin; Pharmacokinetics; Critically ill; Saturation; BETA-LACTAM ANTIBIOTICS; POPULATION PHARMACOKINETIC ANALYSIS; NONLINEAR PHARMACOKINETICS; TAZOBACTAM; PHARMACODYNAMICS; QUANTIFICATION; INTERMITTENT; BOLUS;
D O I
10.1016/j.ijantimicag.2019.08.024
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The study aimed to evaluate saturation of piperacillin elimination in critically ill adult patients. Seventeen critically ill adult patients received continuous and intermittent infusion of piperacillin/tazobactam. Piperacillin plasma concentrations (n = 217) were analysed using population pharmacokinetic (PopPK) modelling. Post-hoc simulations were performed to evaluate the type I error rate associated with the study. Unseen data were used to validate the final model. The mean error (ME) and root mean square error (RMSE) were calculated as a measure of bias and imprecision, respectively. A PopPK model with parallel linear and non-linear elimination best fitted the data. The median and 95% confidence interval (CI) for the model parameters drug clearance (CL), volume of central compartment (V), volume of peripheral compartment (V-p) and intercompartmental clearance (Q) were 9 (7.69-11) L/h, 6.18 (4.93-11.2) L, 11.17 (7.26-12) L and 15.61 (12.66-23.8) L/h, respectively. The Michaelis-Menten constant (K-m) and the maximum elimination rate for Michaelis-Menten elimination (V-max) were estimated without population variability in the model to avoid overfitting and inflation of the type I error rate. The population estimates for K-m and V-max were 37.09 mg/L and 353.57 mg/h, respectively. The bias (ME) was -20.8 (95% CI -26.2 to -15.4) mg/L, whilst imprecision (RMSE) was 49.2 (95% CI 41.2-56) mg/L. In conclusion, piperacillin elimination is (partially) saturable. Moreover, the population estimate for K-m lies within the therapeutic window and therefore saturation of elimination should be accounted for when defining optimum dosing regimens for piperacillin in critically ill patients. (C) 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:741 / 749
页数:9
相关论文
共 42 条
[1]   Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically III Patients [J].
Alobaid, Abdulaziz S. ;
Wallis, Steven C. ;
Jarrett, Paul ;
Starr, Therese ;
Stuart, Janine ;
Lassig-Smith, Melissa ;
Mejia, Jenny Lisette Ordonez ;
Roberts, Michael S. ;
Roger, Claire ;
Udy, Andrew A. ;
Lipman, Jeffrey ;
Roberts, Jason A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (03)
[2]   Mechanism-based concepts of size and maturity in pharmacokinetics [J].
Anderson, B. J. ;
Holford, N. H. G. .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 2008, 48 :303-332
[3]   Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses [J].
Auclair, B ;
Ducharme, MP .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (06) :1465-1468
[4]   What you see may not be what you get: A brief, nontechnical introduction to overfitting in regression-type models [J].
Babyak, MA .
PSYCHOSOMATIC MEDICINE, 2004, 66 (03) :411-421
[5]  
Bolhuis Mathieu S, 2011, Pharmaceutics, V3, P865, DOI 10.3390/pharmaceutics3040865
[6]   Effect of correlation on covariate selection in linear and nonlinear mixed effect models [J].
Bonate, Peter L. .
PHARMACEUTICAL STATISTICS, 2017, 16 (01) :45-54
[7]  
Bonate PL, 2011, PHARMACOKINETIC-PHARMACODYNAMIC MODELING AND SIMULATION, SECOND EDITION, P1, DOI 10.1007/978-1-4419-9485-1
[8]   PIPERACILLIN/TAZOBACTAM - A REVIEW OF ITS ANTIBACTERIAL ACTIVITY, PHARMACOKINETIC PROPERTIES AND THERAPEUTIC POTENTIAL [J].
BRYSON, HM ;
BROGDEN, RN .
DRUGS, 1994, 47 (03) :506-535
[9]   Nonlinear pharmacokinetics of piperacillin in healthy volunteers - implications for optimal dosage regimens [J].
Bulitta, Juergen B. ;
Kinzig, Martina ;
Jakob, Verena ;
Holzgrabe, Ulrike ;
Soergel, Fritz ;
Holford, Nicholas H. G. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (05) :682-693
[10]   Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations [J].
Butterfield, Jill M. ;
Lodise, Thomas P. ;
Beegle, Scott ;
Rosen, Jonathan ;
Farkas, Joshua ;
Pai, Manjunath P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (01) :176-179